ID   22Rv1
AC   CVCL_1045
SY   22RV1; 22Rv-1; 22rV1; CWR-22rv1; CWR22-Rv1; CWR22R-V1; CWR22-R1; CWR22Rv1; CWR22R
DR   BTO; BTO:0002999
DR   CLO; CLO_0001199
DR   CLO; CLO_0001200
DR   EFO; EFO_0002095
DR   ArrayExpress; E-MTAB-38
DR   ArrayExpress; E-MTAB-783
DR   ArrayExpress; E-MTAB-2770
DR   ArrayExpress; E-MTAB-3610
DR   ATCC; CRL-2505
DR   BCRC; 60545
DR   BioGRID_ORCS_Cell_line; 821
DR   BioSample; SAMN03471600
DR   BioSample; SAMN03472052
DR   BioSample; SAMN05292447
DR   BioSample; SAMN07710012
DR   BioSample; SAMN07710013
DR   BioSample; SAMN07710014
DR   BioSample; SAMN07710015
DR   BioSample; SAMN07710016
DR   BioSample; SAMN07710017
DR   BioSample; SAMN07710018
DR   BioSample; SAMN10988315
DR   cancercelllines; CVCL_1045
DR   CCRID; 3101HUMSCSP5022
DR   CCRID; 3101HUMTCHu100
DR   CCRID; 4201HUM-CCTCC00288
DR   CCTCC; GDC0288
DR   Cell_Model_Passport; SIDM00499
DR   ChEMBL-Cells; CHEMBL3308004
DR   ChEMBL-Targets; CHEMBL612657
DR   CLS; 305037
DR   Cosmic; 924100
DR   Cosmic; 1075276
DR   Cosmic; 1028699
DR   Cosmic; 1071480
DR   Cosmic; 1172629
DR   Cosmic; 1330911
DR   Cosmic; 1689707
DR   Cosmic; 1995323
DR   Cosmic; 2537791
DR   Cosmic; 2580126
DR   Cosmic; 2651766
DR   Cosmic; 2669170
DR   Cosmic-CLP; 924100
DR   DepMap; ACH-000956
DR   DSMZ; ACC-438
DR   DSMZCellDive; ACC-438
DR   ECACC; 05092802
DR   EGA; EGAS00001000978
DR   ENCODE; ENCBS070BKF
DR   ENCODE; ENCBS383WOY
DR   ENCODE; ENCBS596KKM
DR   ENCODE; ENCBS626QQL
DR   ENCODE; ENCBS737IZN
DR   ENCODE; ENCBS822DIG
DR   GDSC; 924100
DR   GEO; GSM91926
DR   GEO; GSM525793
DR   GEO; GSM648815
DR   GEO; GSM827396
DR   GEO; GSM886837
DR   GEO; GSM887900
DR   GEO; GSM1374375
DR   GEO; GSM1633317
DR   GEO; GSM1633318
DR   GEO; GSM1633319
DR   GEO; GSM1669565
DR   GEO; GSM3145703
DR   IARC_TP53; 18887
DR   IGRhCellID; 22Rv1
DR   KCB; KCB 200731YJ
DR   LiGeA; CCLE_229
DR   LINCS_LDP; LCL-1145
DR   Lonza; 1442
DR   PharmacoDB; 22RV1_12_2019
DR   PRIDE; PXD030304
DR   Progenetix; CVCL_1045
DR   PubChem_Cell_line; CVCL_1045
DR   Ubigene; YC-C012
DR   Wikidata; Q54583380
RX   CelloPub=CLPUB00698;
RX   DOI=10.5897/IJBMBR2013.0154;
RX   PubMed=10462204;
RX   PubMed=12725112;
RX   PubMed=14518029;
RX   PubMed=14518030;
RX   PubMed=15486987;
RX   PubMed=19403664;
RX   PubMed=20164919;
RX   PubMed=20215515;
RX   PubMed=21248069;
RX   PubMed=22460905;
RX   PubMed=23117885;
RX   PubMed=23671654;
RX   PubMed=25877200;
RX   PubMed=25984343;
RX   PubMed=27271795;
RX   PubMed=27397505;
RX   PubMed=28145883;
RX   PubMed=28928128;
RX   PubMed=30629668;
RX   PubMed=30787054;
RX   PubMed=30894373;
RX   PubMed=30971826;
RX   PubMed=31006810;
RX   PubMed=31068700;
RX   PubMed=31395879;
RX   PubMed=31978347;
RX   PubMed=35839778;
WW   https://www.synapse.org/#!Synapse:syn31544528
WW   https://web.archive.org/web/20160703200709/http://capcelllines.ca:80/details.asp?id=53
WW   https://www.thermofisher.com/ch/en/home/technical-resources/cell-lines/c/cell-lines-detail-524.html
CC   Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).
CC   Part of: COSMIC cell lines project.
CC   Part of: TCGA-110-CL cell line panel.
CC   Population: Caucasian.
CC   Virology: Contains at least 10 integrated copies of xenotropic murine leukemia virus-related virus (XMRV) genome and produces a high titer of the virus (PubMed=19403664; PubMed=30629668).
CC   Doubling time: ~49 hours (PubMed=10462204); 55 hours (PubMed=25984343); 63 hours (Note=From cell counting), 94 hours (Note=From absorbance) (DOI=10.5897/IJBMBR2013.0154); 40 hours (ATCC=CRL-2505); 40-60 hours (DSMZ=ACC-438); ~41 hours (PBCF); 24.07 hours (GrayJW panel).
CC   Microsatellite instability: Instable (MSI-high) (PubMed=23671654; PubMed=31068700; Sanger).
CC   Sequence variation: Mutation; HGNC; 7133; KMT2D; Simple; p.Arg1252Ter (c.3754C>T); ClinVar=VCV000167228; Zygosity=Heterozygous (Cosmic-CLP; DepMap).
CC   Sequence variation: Mutation; HGNC; 7133; KMT2D; Simple; p.Gln3158Ter (c.9472C>T); Zygosity=Heterozygous (Cosmic-CLP; DepMap).
CC   Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Gln546Arg (c.1637A>G); ClinVar=VCV000045466; Zygosity=Heterozygous (Cosmic-CLP; DepMap).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Gln331Arg (c.992A>G); ClinVar=VCV000421319; Zygosity=Heterozygous (PubMed=14518029; ATCC=CRL-2505; Cosmic-CLP; DepMap).
CC   Omics: Array-based CGH.
CC   Omics: CRISPR phenotypic screen.
CC   Omics: Deep exome analysis.
CC   Omics: Deep quantitative proteome analysis.
CC   Omics: DNA methylation analysis.
CC   Omics: shRNA library screening.
CC   Omics: SNP array analysis.
CC   Omics: Transcriptome analysis by microarray.
CC   Omics: Transcriptome analysis by RNAseq.
CC   Genome ancestry: African=0.89%; Native American=0.23%; East Asian, North=0.52%; East Asian, South=0%; South Asian=0.27%; European, North=67.46%; European, South=30.62% (PubMed=30894373).
CC   Derived from site: In situ; Prostate; UBERON=UBERON_0002367.
ST   Source(s): ATCC; Cosmic-CLP; DSMZ; ECACC; PubMed=14518029; PubMed=25877200; PubMed=27271795; PubMed=31006810
ST   Amelogenin: X,Y
ST   CSF1PO: 10,11
ST   D13S317: 8,9,12 (PubMed=14518029)
ST   D13S317: 9,12 (DSMZ; PubMed=25877200; PubMed=27271795; PubMed=31006810)
ST   D16S539: 12
ST   D18S51: 13,14
ST   D19S433: 13,14
ST   D21S11: 30
ST   D2S1338: 17,18
ST   D3S1358: 14,15 (PubMed=14518029)
ST   D3S1358: 15 (DSMZ; PubMed=25877200; PubMed=27271795)
ST   D5S818: 11,12 (Cosmic-CLP; ECACC; PubMed=31006810)
ST   D5S818: 11,12,13 (ATCC; DSMZ; PubMed=14518029)
ST   D5S818: 11,13 (PubMed=25877200; PubMed=27271795)
ST   D7S820: 9,10,11 (ATCC; DSMZ; PubMed=25877200; PubMed=27271795)
ST   D7S820: 10,11 (Cosmic-CLP; ECACC; PubMed=14518029; PubMed=31006810)
ST   D8S1179: 12,13,14 (DSMZ; PubMed=14518029; PubMed=27271795)
ST   D8S1179: 13,14 (PubMed=25877200)
ST   FGA: 20,23
ST   Penta D: 9,12
ST   Penta E: 5,13
ST   TH01: 6,9.3
ST   TPOX: 8
ST   vWA: 14,15,20,21 (DSMZ)
ST   vWA: 15,20,21 (PubMed=14518029)
ST   vWA: 15,21 (ATCC; Cosmic-CLP; ECACC; PubMed=25877200; PubMed=27271795; PubMed=31006810)
DI   NCIt; C4863; Prostate carcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_3967 ! CWR22
SX   Male
AG   Adult
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 30-01-24; Version: 46
//
RX   CelloPub=CLPUB00698;
RA   van Bokhoven A.;
RT   "Models for prostate cancer. Molecular characterization and critical
RT   appraisal of human prostate carcinoma cell lines.";
RL   Thesis PhD (2004), Katholieke Universiteit Nijmegen, Netherlands.
//
RX   DOI=10.5897/IJBMBR2013.0154;
RA   Iloki Assanga S.B., Gil-Salido A.A., Lewis Lujan L.M., Rosas-Durazo A.,
RA   Acosta-Silva A.L., Rivera-Castaneda E.G., Rubio-Pino J.L.;
RT   "Cell growth curves for different cell lines and their relationship
RT   with biological activities.";
RL   Int. J. Biotechnol. Mol. Biol. Res. 4:60-70(2013).
//
RX   PubMed=10462204; DOI=10.1007/s11626-999-0115-4;
RA   Sramkoski R.M., Pretlow T.G. II, Giaconia J.M., Pretlow T.P.,
RA   Schwartz S., Sy M.-S., Marengo S.R., Rhim J.S., Zhang D.,
RA   Jacobberger J.W.;
RT   "A new human prostate carcinoma cell line, 22Rv1.";
RL   In Vitro Cell. Dev. Biol. Anim. 35:403-409(1999).
//
RX   PubMed=12725112; DOI=10.1385/1-59259-372-0:21;
RA   Russell P.J., Kingsley E.A.;
RT   "Human prostate cancer cell lines.";
RL   Methods Mol. Med. 81:21-39(2003).
//
RX   PubMed=14518029; DOI=10.1002/pros.10290;
RA   van Bokhoven A., Varella-Garcia M., Korch C.T., Johannes W.U.,
RA   Smith E.E., Miller H.L., Nordeen S.K., Miller G.J., Lucia M.S.;
RT   "Molecular characterization of human prostate carcinoma cell lines.";
RL   Prostate 57:205-225(2003).
//
RX   PubMed=14518030; DOI=10.1002/pros.10291;
RA   van Bokhoven A., Caires A., Di Maria M., Schulte A.P., Lucia M.S.,
RA   Nordeen S.K., Miller G.J., Varella-Garcia M.;
RT   "Spectral karyotype (SKY) analysis of human prostate carcinoma cell
RT   lines.";
RL   Prostate 57:226-244(2003).
//
RX   PubMed=15486987; DOI=10.1002/pros.20158;
RA   Zhao H.-J., Kim Y., Wang P., Lapointe J., Tibshirani R., Pollack J.R.,
RA   Brooks J.D.;
RT   "Genome-wide characterization of gene expression variations and DNA
RT   copy number changes in prostate cancer cell lines.";
RL   Prostate 63:187-197(2005).
//
RX   PubMed=19403664; DOI=10.1128/JVI.00546-09;
RA   Knouf E.C., Metzger M.J., Mitchell P.S., Arroyo J.D., Chevillet J.R.,
RA   Tewari M., Miller A.D.;
RT   "Multiple integrated copies and high-level production of the human
RT   retrovirus XMRV (xenotropic murine leukemia virus-related virus) from
RT   22Rv1 prostate carcinoma cells.";
RL   J. Virol. 83:7353-7356(2009).
//
RX   PubMed=20164919; DOI=10.1038/nature08768;
RA   Bignell G.R., Greenman C.D., Davies H., Butler A.P., Edkins S.,
RA   Andrews J.M., Buck G., Chen L., Beare D., Latimer C., Widaa S.,
RA   Hinton J., Fahey C., Fu B.-Y., Swamy S., Dalgliesh G.L., Teh B.T.,
RA   Deloukas P., Yang F.-T., Campbell P.J., Futreal P.A., Stratton M.R.;
RT   "Signatures of mutation and selection in the cancer genome.";
RL   Nature 463:893-898(2010).
//
RX   PubMed=20215515; DOI=10.1158/0008-5472.CAN-09-3458;
RA   Rothenberg S.M., Mohapatra G., Rivera M.N., Winokur D., Greninger P.,
RA   Nitta M., Sadow P.M., Sooriyakumar G., Brannigan B.W., Ulman M.J.,
RA   Perera R.M., Wang R., Tam A., Ma X.-J., Erlander M., Sgroi D.C.,
RA   Rocco J.W., Lingen M.W., Cohen E.E.W., Louis D.N., Settleman J.,
RA   Haber D.A.;
RT   "A genome-wide screen for microdeletions reveals disruption of
RT   polarity complex genes in diverse human cancers.";
RL   Cancer Res. 70:2158-2164(2010).
//
RX   PubMed=21248069; DOI=10.1158/0008-5472.CAN-10-1998;
RA   Li Y.-M., Alsagabi M., Fan D.-H., Bova G.S., Tewfik A.H., Dehm S.M.;
RT   "Intragenic rearrangement and altered RNA splicing of the androgen
RT   receptor in a cell-based model of prostate cancer progression.";
RL   Cancer Res. 71:2108-2117(2011).
//
RX   PubMed=22460905; DOI=10.1038/nature11003;
RA   Barretina J.G., Caponigro G., Stransky N., Venkatesan K., Margolin A.A.,
RA   Kim S., Wilson C.J., Lehar J., Kryukov G.V., Sonkin D., Reddy A.,
RA   Liu M., Murray L., Berger M.F., Monahan J.E., Morais P., Meltzer J.,
RA   Korejwa A., Jane-Valbuena J., Mapa F.A., Thibault J., Bric-Furlong E.,
RA   Raman P., Shipway A., Engels I.H., Cheng J., Yu G.-Y.K., Yu J.-J.,
RA   Aspesi P. Jr., de Silva M., Jagtap K., Jones M.D., Wang L., Hatton C.,
RA   Palescandolo E., Gupta S., Mahan S., Sougnez C., Onofrio R.C.,
RA   Liefeld T., MacConaill L.E., Winckler W., Reich M., Li N.-X., Mesirov J.P.,
RA   Gabriel S.B., Getz G., Ardlie K., Chan V., Myer V.E., Weber B.L.,
RA   Porter J., Warmuth M., Finan P., Harris J.L., Meyerson M.L., Golub T.R.,
RA   Morrissey M.P., Sellers W.R., Schlegel R., Garraway L.A.;
RT   "The Cancer Cell Line Encyclopedia enables predictive modelling of
RT   anticancer drug sensitivity.";
RL   Nature 483:603-607(2012).
//
RX   PubMed=23117885; DOI=10.1158/0008-5472.CAN-12-3630;
RA   Li Y.-M., Chan S.-C., Brand L.J., Hwang T.H., Silverstein K.A.T.,
RA   Dehm S.M.;
RT   "Androgen receptor splice variants mediate enzalutamide resistance in
RT   castration-resistant prostate cancer cell lines.";
RL   Cancer Res. 73:483-489(2013).
//
RX   PubMed=23671654; DOI=10.1371/journal.pone.0063056;
RA   Lu Y.-H., Soong T.D., Elemento O.;
RT   "A novel approach for characterizing microsatellite instability in
RT   cancer cells.";
RL   PLoS ONE 8:E63056-E63056(2013).
//
RX   PubMed=25877200; DOI=10.1038/nature14397;
RA   Yu M., Selvaraj S.K., Liang-Chu M.M.Y., Aghajani S., Busse M.,
RA   Yuan J., Lee G., Peale F.V., Klijn C., Bourgon R., Kaminker J.S.,
RA   Neve R.M.;
RT   "A resource for cell line authentication, annotation and quality
RT   control.";
RL   Nature 520:307-311(2015).
//
RX   PubMed=25984343; DOI=10.1038/sdata.2014.35;
RA   Cowley G.S., Weir B.A., Vazquez F., Tamayo P., Scott J.A., Rusin S.,
RA   East-Seletsky A., Ali L.D., Gerath W.F.J., Pantel S.E., Lizotte P.H.,
RA   Jiang G.-Z., Hsiao J., Tsherniak A., Dwinell E., Aoyama S., Okamoto M.,
RA   Harrington W., Gelfand E.T., Green T.M., Tomko M.J., Gopal S.,
RA   Wong T.C., Li H.-B., Howell S., Stransky N., Liefeld T., Jang D.,
RA   Bistline J., Meyers B.H., Armstrong S.A., Anderson K.C.,
RA   Stegmaier K., Reich M., Pellman D., Boehm J.S., Mesirov J.P.,
RA   Golub T.R., Root D.E., Hahn W.C.;
RT   "Parallel genome-scale loss of function screens in 216 cancer cell
RT   lines for the identification of context-specific genetic
RT   dependencies.";
RL   Sci. Data 1:140035-140035(2014).
//
RX   PubMed=27271795; DOI=10.1002/pros.23190;
RA   Shourideh M., DePriest A., Mohler J.L., Wilson E.M., Koochekpour S.;
RT   "Characterization of fibroblast-free CWR-R1ca castration-recurrent
RT   prostate cancer cell line.";
RL   Prostate 76:1067-1077(2016).
//
RX   PubMed=27397505; DOI=10.1016/j.cell.2016.06.017;
RA   Iorio F., Knijnenburg T.A., Vis D.J., Bignell G.R., Menden M.P.,
RA   Schubert M., Aben N., Goncalves E., Barthorpe S., Lightfoot H.,
RA   Cokelaer T., Greninger P., van Dyk E., Chang H., de Silva H., Heyn H.,
RA   Deng X.-M., Egan R.K., Liu Q.-S., Mironenko T., Mitropoulos X.,
RA   Richardson L., Wang J.-H., Zhang T.-H., Moran S., Sayols S.,
RA   Soleimani M., Tamborero D., Lopez-Bigas N., Ross-Macdonald P.,
RA   Esteller M., Gray N.S., Haber D.A., Stratton M.R., Benes C.H.,
RA   Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.;
RT   "A landscape of pharmacogenomic interactions in cancer.";
RL   Cell 166:740-754(2016).
//
RX   PubMed=28145883; DOI=10.18632/oncotarget.14850;
RA   Nouri M., Caradec J., Lubik A.A., Li N., Hollier B.G., Takhar M.,
RA   Altimirano-Dimas M., Chen M.-Q., Roshan-Moniri M., Butler M., Lehman M.,
RA   Bishop J., Truong S., Huang S.-C., Cochrane D., Cox M., Collins C.,
RA   Gleave M.E., Erho N., Alshalafa M., Davicioni E., Nelson C.,
RA   Gregory-Evans S., Karnes R.J., Jenkins R.B., Klein E.A., Buttyan R.;
RT   "Therapy-induced developmental reprogramming of prostate cancer cells
RT   and acquired therapy resistance.";
RL   Oncotarget 8:18949-18967(2017).
//
RX   PubMed=28928128; DOI=10.1158/0008-5472.CAN-17-0320;
RA   Van Etten J.L., Nyquist M., Li Y.-M., Yang R.-D., Ho Y., Johnson R.,
RA   Ondigi O., Voytas D.F., Henzler C., Dehm S.M.;
RT   "Targeting a single alternative polyadenylation site coordinately
RT   blocks expression of androgen receptor mRNA splice variants in
RT   prostate cancer.";
RL   Cancer Res. 77:5228-5235(2017).
//
RX   PubMed=30629668; DOI=10.1371/journal.pone.0210404;
RA   Uphoff C.C., Pommerenke C., Denkmann S.A., Drexler H.G.;
RT   "Screening human cell lines for viral infections applying RNA-Seq data
RT   analysis.";
RL   PLoS ONE 14:E0210404-E0210404(2019).
//
RX   PubMed=30787054; DOI=10.1158/1055-9965.EPI-18-1132;
RA   Hooker S.E. Jr., Woods-Burnham L., Bathina M., Lloyd S., Gorjala P.,
RA   Mitra R., Nonn L., Kimbro K.S., Kittles R.A.;
RT   "Genetic ancestry analysis reveals misclassification of commonly used
RT   cancer cell lines.";
RL   Cancer Epidemiol. Biomarkers Prev. 28:1003-1009(2019).
//
RX   PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747;
RA   Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.;
RT   "An interactive resource to probe genetic diversity and estimated
RT   ancestry in cancer cell lines.";
RL   Cancer Res. 79:1263-1273(2019).
//
RX   PubMed=30971826; DOI=10.1038/s41586-019-1103-9;
RA   Behan F.M., Iorio F., Picco G., Goncalves E., Beaver C.M.,
RA   Migliardi G., Santos R., Rao Y., Sassi F., Pinnelli M., Ansari R.,
RA   Harper S., Jackson D.A., McRae R., Pooley R., Wilkinson P.,
RA   van der Meer D.J., Dow D., Buser-Doepner C.A., Bertotti A., Trusolino L.,
RA   Stronach E.A., Saez-Rodriguez J., Yusa K., Garnett M.J.;
RT   "Prioritization of cancer therapeutic targets using CRISPR-Cas9
RT   screens.";
RL   Nature 568:511-516(2019).
//
RX   PubMed=31006810; DOI=10.1093/nar/gkz286;
RA   Kounatidou E., Nakjang S., McCracken S.R.C., Dehm S.M., Robson C.N.,
RA   Jones D., Gaughan L.;
RT   "A novel CRISPR-engineered prostate cancer cell line defines the AR-V
RT   transcriptome and identifies PARP inhibitor sensitivities.";
RL   Nucleic Acids Res. 47:5634-5647(2019).
//
RX   PubMed=31068700; DOI=10.1038/s41586-019-1186-3;
RA   Ghandi M., Huang F.W., Jane-Valbuena J., Kryukov G.V., Lo C.C.,
RA   McDonald E.R. III, Barretina J.G., Gelfand E.T., Bielski C.M., Li H.-X.,
RA   Hu K., Andreev-Drakhlin A.Y., Kim J., Hess J.M., Haas B.J., Aguet F.,
RA   Weir B.A., Rothberg M.V., Paolella B.R., Lawrence M.S., Akbani R.,
RA   Lu Y.-L., Tiv H.L., Gokhale P.C., de Weck A., Mansour A.A., Oh C.,
RA   Shih J., Hadi K., Rosen Y., Bistline J., Venkatesan K., Reddy A.,
RA   Sonkin D., Liu M., Lehar J., Korn J.M., Porter D.A., Jones M.D.,
RA   Golji J., Caponigro G., Taylor J.E., Dunning C.M., Creech A.L.,
RA   Warren A.C., McFarland J.M., Zamanighomi M., Kauffmann A.,
RA   Stransky N., Imielinski M., Maruvka Y.E., Cherniack A.D.,
RA   Tsherniak A., Vazquez F., Jaffe J.D., Lane A.A., Weinstock D.M.,
RA   Johannessen C.M., Morrissey M.P., Stegmeier F., Schlegel R.,
RA   Hahn W.C., Getz G., Mills G.B., Boehm J.S., Golub T.R., Garraway L.A.,
RA   Sellers W.R.;
RT   "Next-generation characterization of the Cancer Cell Line
RT   Encyclopedia.";
RL   Nature 569:503-508(2019).
//
RX   PubMed=31395879; DOI=10.1038/s41467-019-11415-2;
RA   Yu K., Chen B., Aran D., Charalel J., Yau C., Wolf D.M.,
RA   van 't Veer L.J., Butte A.J., Goldstein T., Sirota M.;
RT   "Comprehensive transcriptomic analysis of cell lines as models of
RT   primary tumors across 22 tumor types.";
RL   Nat. Commun. 10:3574.1-3574.11(2019).
//
RX   PubMed=31978347; DOI=10.1016/j.cell.2019.12.023;
RA   Nusinow D.P., Szpyt J., Ghandi M., Rose C.M., McDonald E.R. III,
RA   Kalocsay M., Jane-Valbuena J., Gelfand E.T., Schweppe D.K.,
RA   Jedrychowski M.P., Golji J., Porter D.A., Rejtar T., Wang Y.K.,
RA   Kryukov G.V., Stegmeier F., Erickson B.K., Garraway L.A.,
RA   Sellers W.R., Gygi S.P.;
RT   "Quantitative proteomics of the Cancer Cell Line Encyclopedia.";
RL   Cell 180:387-402.e16(2020).
//
RX   PubMed=35839778; DOI=10.1016/j.ccell.2022.06.010;
RA   Goncalves E., Poulos R.C., Cai Z.-X., Barthorpe S., Manda S.S., Lucas N.,
RA   Beck A., Bucio-Noble D., Dausmann M., Hall C., Hecker M., Koh J.,
RA   Lightfoot H., Mahboob S., Mali I., Morris J., Richardson L.,
RA   Seneviratne A.J., Shepherd R., Sykes E., Thomas F., Valentini S.,
RA   Williams S.G., Wu Y.-X., Xavier D., MacKenzie K.L., Hains P.G., Tully B.,
RA   Robinson P.J., Zhong Q., Garnett M.J., Reddel R.R.;
RT   "Pan-cancer proteomic map of 949 human cell lines.";
RL   Cancer Cell 40:835-849.e8(2022).
//